E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar.

Cited by (1)

Abstract
Background: The introduction of stents and the use of platelet glycoprotein IIb/IIIa inhibitors, either alone or in combination with reduced-dose fibrinolytic therapy, has allowed percutaneous coronary intervention (PCI) to be performed more safely and synergistically following pharmacologic reperfusion therapy.

Aims and Objectives: The present study was conducted to evaluate the efficacy and safety of tirofiban as an adjunct to angioplasty/stenting in acute ST-elevation myocardial infarction (MI) patients.

Materials and Methods: A total of 156 consecutive patients diagnosed with acute ST-segment elevation MI (STEMI) presenting within 12 h of symptoms were randomly allocated to primary PCI alone or primary PCI along with tirofiban. Clinical characteristics, angiographic findings (including thrombolysis in MI [TIMI] flow rate), and ST-segment resolution were compared post-procedurally; left ventricular ejection fraction (LVEF) and major adverse cardiac events (MACE, including death, reinfarction, and target vessel revascularization) were compared at 30 days clinical follow-up.

Results: Post-procedurally, TIMI Grade 3 reflow was significantly different between two groups (P = 0.01) and was associated with better in-hospital outcomes in tirofiban group compared with control group. Greater resolution of ST-elevation was achieved in patients given tirofiban than in non-tirofiban group, and the results were highly significant. Statistically significant improvement in LVEF was also observed in tirofiban group. There was non-significant difference in MACE and bleeding complications between two groups.

Conclusion: Adjunctive tirofiban therapy for patients with acute STEMI, who underwent primary PCI, seems to be safe and effective treatment modality to achieve improved reperfusion, better LVEF, and clinical outcome at 30 days follow-up.

Key words: Tirofiban; Percutaneous Coronary Intervention; ST-segment Elevation Myocardial Infarction


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Sanjay Sharma
Articles by Seema Gupta
Articles by Sanjeev Bhat
Articles by Zahid Gillani
Articles by Dinesh Kumar
Articles by Rajesh Kumar
on Google
on Google Scholar


REFERENCES
1. Seth A, Patel TM, Stuteville M, Kumar R, Mullasari AS, Kaul U, et al. Three-year data from the XIENCE V INDIA study: Safety and efficacy of XIENCE V in 1000 real world Indian patients. Indian Heart J. 2014;66(3):302-8. https://doi.org/10.1016/j.ihj.2014.03.007 [Pubmed]    [PMC Free Fulltext]   
2. Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, et al. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis 2008;19(4):271-7. https://doi.org/10.1097/MCA.0b013e3282f487e0 [Pubmed]   
3. Shen WF. Evolution of interventional cardiology in China. Chin Med J (Engl). 2009;122(19):2209-19.
4. Liu T, Xie Y, Zhou YJ, Li YP, Ma HY, Guo YH, et al. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions. Chin Med J (Engl). 2009;122(15):1732-7.
5. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, et al. Platelet reactivity characterized prospectively: A determinant of outcome 90 days after percutaneous coronary intervention. Circulation. 2001;104(2):181-6. https://doi.org/10.1161/01.CIR.104.2.181 [Pubmed]   
6. Bolognese L. The emerging role of platelet glycoprotein IIb/ IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes. Curr Med Res Opin. 2007;23(6):1217-26. https://doi.org/10.1185/030079907X188143 [Pubmed]   
7. Galal H, Essmat E. Impact of upstream high bolus dose tirofiban on left ventricular systolic function in patients with acute anterior myocardial infarction treated by primary coronary intervention. Egypt Heart J. 2014;66(3):251-7. https://doi.org/10.1016/j.ehj.2014.05.003
8. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI), Phase II Trial. Ann Intern Med. 1991;115(4):256-65. https://doi.org/10.7326/0003-4819-115-4-256 [Pubmed]   
9. Ryan J, Cohen DJ, Pinto DS. Drug-eluting stents for ST[corrected]-elevation acute myocardial infarction: Do we need randomized trials? Coron Artery Dis. 2006;17(8):667-71. https://doi.org/10.1097/MCA.0b013e3280111042 [Pubmed]   
10. Manoria PC, Manoria P, Manoria P, Shrivastava RK, Parashar SK. Antiplatelet drugs for PCI: Current scenario. Cardiol Today 2016;xx(1):5-14.
11. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344(25):1895-903. https://doi.org/10.1056/NEJM200106213442503 [Pubmed]   
12. Danzi GB, Sesana M, Capuano C, Mauri L, Berra Centurini P, Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol. 2004;94(1):35-9. https://doi.org/10.1016/j.amjcard.2004.03.026 [Pubmed]   
13. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41(1):26-32. https://doi.org/10.1016/S0735-1097(02)02666-9
14. Cannon CP, Braunwald E. Time to Reperfusion: The critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombolysis. 1996;3(2):117-125.
15. Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: Results of the tirofiban given in the emergency room before primary angioplasty (TIGER-PA) pilot trial. Circulation. 2003;107(11):1497-501. https://doi.org/10.1161/01.CIR.0000056120.00513.7A [Pubmed]   
16. Wu TG, Zhao Q, Huang WG, Wei JR, Chen SW, Zhao J, et al. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ J. 2008;72(10):1605-9. https://doi.org/10.1253/circj.CJ-08-0357
17. Fu XH, Hao QQ, Jia XW, Fan WZ, Gu XS, Wu WL, et al. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chin Med J (Engl). 2008;121(6):522-7.
18. Peng JJ, Ma ZM, Ren LH, Ma ZM, Ren LH, Fu GQ, et al. Effect of tirofiban in acute anterior myocardial infarction patients without ST segment resolution after primary percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37(8):725-8.
19. Li SY, Yan HB, Wang J, Song L, Wu Z, Chi YP, et al. Efficiency and safety of thrombus aspiration plus intra-infarct-related artery administration of tirofiban during primary angioplasty. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38(10):880-5.
20. Yan HB, Li SY, Song L, Wang J, Wu Z, Chi YP, et al. Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction. Chin Med J (Engl). 2010;123(7):877-83.
21. Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, et al. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: Preliminary results from the TETAMI registry and randomized trial. Circulation. 2003;108 16 Suppl 1:III14-21.
22. Shah A, Wagner GS, Granger CB, O'Connor CM, Green CL, Trollinger KM, et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. J Am Coll Cardiol. 2000;35(3):666-72. https://doi.org/10.1016/S0735-1097(99)00601-4
23. Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - Results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J. 2004;25:2125-33. https://doi.org/10.1016/j.ehj.2004.09.018 [Pubmed]   
24. De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: An individual patient data meta-analysis. Heart. 2008;94(12):1548-58. https://doi.org/10.1136/hrt.2008.141648 [Pubmed]    [PMC Free Fulltext]   
25. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The restore investigators. Randomized efficacy study of tirofiban for outcomes and restenosis. Circulation. 1997;96(5):1445-53.

This Article Cited By the following articles

Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis
Canadian Journal of Cardiology 2019; (): .

1
 
How to Cite this Article
Pubmed Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. Natl J Physiol Pharm Pharmacol. 2016; 6(6): 531-536. doi:10.5455/njppp.2016.6.0512413062016


Web Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. https://www.njppp.com/?mno=226747 [Access: December 01, 2022]. doi:10.5455/njppp.2016.6.0512413062016


AMA (American Medical Association) Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. Natl J Physiol Pharm Pharmacol. 2016; 6(6): 531-536. doi:10.5455/njppp.2016.6.0512413062016



Vancouver/ICMJE Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. Natl J Physiol Pharm Pharmacol. (2016), [cited December 01, 2022]; 6(6): 531-536. doi:10.5455/njppp.2016.6.0512413062016



Harvard Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar (2016) Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. Natl J Physiol Pharm Pharmacol, 6 (6), 531-536. doi:10.5455/njppp.2016.6.0512413062016



Turabian Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. 2016. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. National Journal of Physiology, Pharmacy and Pharmacology, 6 (6), 531-536. doi:10.5455/njppp.2016.6.0512413062016



Chicago Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. "Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty." National Journal of Physiology, Pharmacy and Pharmacology 6 (2016), 531-536. doi:10.5455/njppp.2016.6.0512413062016



MLA (The Modern Language Association) Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. "Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty." National Journal of Physiology, Pharmacy and Pharmacology 6.6 (2016), 531-536. Print. doi:10.5455/njppp.2016.6.0512413062016



APA (American Psychological Association) Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar (2016) Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. National Journal of Physiology, Pharmacy and Pharmacology, 6 (6), 531-536. doi:10.5455/njppp.2016.6.0512413062016